CSL logo
CSL
CSLLY | OTC
Chart Builder DCF Calculator
$34.00
-$0.41 (-1.19%)
At close: Nov 16, 2026, 3:59 PM ET
$34.00
$0.00 (0.00%)
After-hours: Nov 16, 2026, 3:59 PM ET

CSL Company Profile

Company profile explained

Company Profile

CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies, which are crucial for treating serious medical conditions including immunodeficiency, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. This division also conducts extensive research into both plasma and non-plasma-based treatments and generates income through licensing agreements and royalties from its proprietary innovations. In contrast, the Seqirus segment is focused on manufacturing and supplying biotherapeutic products that are not derived from plasma, with a particular emphasis on the development of solutions related to influenza. CSL Limited, originally founded in 1916, has its corporate headquarters situated in Parkville, Australia.

Key Executives

Name Position
Gordon Naylor DipCompSc MD, Chief Executive Officer & Executive Director
Amy Van Buren Chief People Officer
Ken Lim Chief Financial Officer
Gregory Boss Executive VP of Legal & Group General Counsel
Herve Gisserot Executive VP of Business Development & Enterprise Alliance Management
Kate Sophie Priestman Chief Corporate & External Affairs Officer
Mark Dehring Head of Investor Relations
Mark Hill Chief Digital Information Officer & Executive Vice President
Mary Oates Executive VP & COO
Michelle Rees Head of Investor Relations
Stephen Marlow Executive VP & GM of CSL Plasma
William Mezzanotte Chief Medical Officer, Executive Vice President and Head of Research & Development
CSL
CSL logo
Country Australia
IPO Date Dec 29, 2009
Industry Biotechnology
Sector Healthcare
Employees 29,000
CEO Gordon Naylor DipCompSc

Contact Details

655 Elizabeth Street Melbourne, VIC 3000 Australia

Stock Details

Ticker Symbol CSLLY
Exchange OTC
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001274152
CUSIP Number 12637N204
ISIN Number US12637N2045
SIC Code

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.